Recent advances in the clinical applications of female anti-Müllerian hormone

doi:10.3877/cma.j.issn.2095-5820.2015.04.006

Abstract

Abstract:

Female anti-Müllerian hormone(AMH) is derived from the early follicular granulosa cells, which plays an important role in the regulation of follicular maturation. AMH is one of the indicators of the diagnosis and tracking of ovarian reserve function and polycystic ovary syndrome (PCOS), and also can be used as a tumor marker in the diagnosis, treatment and recurrence of ovarian tumors. In the field of assisted reproduction, AMH assay is helpful to the individualized administration of ovarian hyper stimulation to improve the efficiency and safety of in vitro fertilization (IVF). The wide application of AMH in clinical practice is helpful to provide a reference for the individualized and rational treatment.

Key words: Anti-müllerian hormone, Ovarian reserve, Tumor, Assisted reproductive

Chaoyan Yue, Chunmei Ying. Recent advances in the clinical applications of female anti-Müllerian hormone[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2015, 03(04): 217-220.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2015.04.006

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2015/V03/I04/217

References 40

[1]	Wilson JD, George FW, Griffin JE. The hormonal control of sexual development[J]. Science, 1981, 211(4488):1278–1284.
[2]	Teixeira J, Maheswaran S, Donahoe PK. Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications[J]. Endocr Rev, 2001, 22(5):657–674.
[3]	Salhi I, Cambon-Roques S, Lamarre I, et al. The anti-Mullerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand[J]. Biochem J, 2004, 379(Pt 3):785–793.
[4]	de Vet A, Laven JSE, de Jong FH, et al. Anti-Mullerian Hormone serum levels: A putative marker for ovarian aging[J]. Fertil Steril, 2002, 77(2):357–362.
[5]	Hansen KR, Hodnett GM, Knowlton N, et al. Correlation of ovarian reserve tests with histologically determined primordial follicle number[J]. Fertil Steril, 2011, 95(1):170–175.
[6]	Hagen CP, Aksglaede L, Sorensen K, et al. Serum levels of anti-Mullerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients[J]. J Clin Endocrinol Metab, 2010, 95(11):5003–5010.
[7]	Kelsey TW, Wright P, Nelson SM, et al. A validated model of serum anti-mullerian hormone from conception to menopause[J]. PLoS One, 2011, 6(7):e22024.
[8]	Lie Fong S, Visser JA, Welt CK, et al. Serum anti-mullerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood[J]. J Clin Endocrinol Metab, 2012, 97(12):4650–4655.
[9]	teVelde ER, Pearson PL. The variability of female reproductive ageing[J]. Hum Reprod Update, 2002, 8(2):141–154.
[10]	Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences[J]. Endocr Rev, 2009, 30(5):465–493.
[11]	Broer SL, Eijkemans MJ, Scheffer GJ, et al. Anti-mullerian hormone predicts menopause: along-term follow-up study in normoovulatorywomen[J]. J Clin Endocrinol Metab, 2011, 96(8):2532–2539.
[12]	Freeman EW, Sammel MD, Lin H, Gracia CR. Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women[J]. J Clin Endocrinol Metab, 2012, 97(5):1673–1680.
[13]	Dolleman M, Faddy MJ, van Disseldorp J, et al. The relationship between anti-Mullerian hormone in women receiving fertility assessments and age at menopause in subfertile women: evidence from large population studies[J]. J Clin Endocrinol Metab, 2013a 98(5):1946–1953.
[14]	Dewailly D, Gronier H, Poncelet E, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries[J]. Hum Reprod, 2011, 26(11):3123–3129.
[15]	Dewailly D, Lujan ME, Carmina E, et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society[J]. Hum Reprod Update, 2014, 20(3):334–352.
[16]	Eilertsen TB, Vanky E, Carlsen SM. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?[J]. Hum Reprod, 2012, 27(8):2494–2502.
[17]	Laven JS, Mulders AG, Visser JA, et al. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age[J]. J Clin Endocrinol Metab, 2004, 89(1):318–323.
[18]	Piouka A, Farmakiotis D, Katsikis I, et al. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels[J]. Am J Physiol Endocrinol Metab, 2009, 29–6(2):E238–E243.
[19]	Iliodromiti S, Kelsey TW, Anderson RA, et al. Can anti-mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data[J]. J Clin Endocrinol Metab, 2013, 98(8):3332–3340.
[20]	Baker VL. Primary ovarian insufficiency in the adolescent[J]. Curr Opin Obstet Gynecol, 2013, 25(5):375–381.
[21]	Leader B, Bakerb VL. Maximizing the clinical utility of antimullerian hormone testing in women’s health[J]. Curr Opin Obstet Gynecol, 2014, 26(4):226–236.
[22]	Lane AH, Lee MM, Fuller AF Jr, et al. Diagnostic utility of Mullerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors[J]. Gynecol Oncol, 1999, 73(1):51–55.
[23]	Mancaux A, GrardelChambenoit E, Gagneur O, et al. Granulosa cell tumor: difficulty of diagnosis and contribution of imaging[J]. Gynecol Obstet Fertil, 2013, 41(7–8):439–445.
[24]	Ha TU, Segev DL, Barbie D, et al. Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism[J]. J Biol Chem, 2000, 275(47):37101–37109.
[25]	Stephen AE, Pearsall LA, Christian BP, et al. Highly purified mullerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res, 2002, 8(8):2640–2646.
[26]	Berkenblit A, Cannistra SA. Advances in the management of epithelial ovarian cancer[J]. J Reprod Med, 2005, 50(6):426–438.
[27]	Renaud EJ, MacLaughlin DT, Oliva E, et al. Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance[J]. Proc Natl Acad Sci, 2005, 102(1):111–116.
[28]	Kim JH, MacLaughlin DT, Donahoe PK. Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumors[J]. Obstet Gynecol Sci, 2014, 57(5):343–357.
[29]	Yates AP, Rustamov O, Roberts SA, et al. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF[J]. Hum Reprod, 2011, 26(9):2353–2362.
[30]	La Marca A, Papaleo E, Grisendi V, et al. Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in vitro fertilisation cycles[J]. BJOG, 2012, 119(10):1171–1179.
[31]	Broer SL, van DJ, Broeze KA, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach[J]. Hum Reprod Update, 2013b 19(1):26–36.
[32]	Arce JC, La MA, Mirner KB, et al. Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients[J]. Fertil Steril, 2013, 99(6):1644–1653.
[33]	Brodin T, Hadziosmanovic N, Berglund L, et al. Antimullerian hormone levels are strongly associated with live-birth rates after assisted reproduction[J]. J Clin Endocrinol Metab, 2013, 98(3):1107–1114.
[34]	La Marca A, Nelson SM, Sighinolfi G, et al. Anti-Mullerian hormone-based prediction model for a live birth in assisted reproduction[J]. Reprod Biomed Online, 2011, 22(4):341–349.
[35]	Namkung J, Song JY, Jo HH, et al. Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis[J]. J Clin Endocrinol Metab, 2012, 97(9):3224–3230.
[36]	Borahay MA, Lu F, Ozpolat B, et al. Mullerian inhibiting substance suppresses proliferation and induces apoptosis and autophagy in endometriosis cells in vitro[J]. ISRN Obstet Gynecol, 2013, 2013:361489.
[37]	Fabregues F, Castelo-Branco C, Carmona F, et al. The effect of differentvhormone therapies on antimullerian hormone serum levels in anovulatoryvwomen of reproductive age[J]. Gynecol Endocrinol, 2011, 27(4):216–224.
[38]	Mes-Krowinkel MG, Louwers YV, Mulders AG, et al. Influence of oral contraceptivesvonanthropomorphometric, endocrine, and metabolic profiles ofvanovulatory polycystic ovary syndrome patients[J]. Fertil Steril, 2014, 101(6):1757–1765.
[39]	Broer SL, Broekmans FJ, Laven JS, et al. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications[J]. Hum Reprod Update, 2014, 20(5):688–701.
[40]	Dolleman M, Verschuren WM, Eijkemans MJ, et al. Reproductive and lifestyle determinants of anti-Mullerian hormone in a large population-based study[J]. J Clin Endocrinol Metab, 2013b 98(5):2106–2115.

Please choose a citation manager

Content to export